Nasonex Nasal Spray Dosing and Administration for Chronic Rhinitis with Epistaxis
For chronic rhinitis with epistaxis, use Nasonex (mometasone furoate) 2 sprays per nostril once daily (200 mcg total) for patients ≥12 years, or 1 spray per nostril once daily (100 mcg total) for children 2-11 years, with careful instruction to direct sprays AWAY from the nasal septum to minimize bleeding risk. 1
Age-Specific Dosing
Adults and adolescents (≥12 years):
- Standard dose: 2 sprays per nostril once daily (200 mcg total dose)
- Each spray delivers 50 mcg of mometasone furoate 1
Children (2-11 years):
- Recommended dose: 1 spray per nostril once daily (100 mcg total dose)
- The 100 mcg dose provides optimal efficacy without additional benefit from higher doses 2
Children under 2 years:
- Not FDA-approved for this age group 1
Critical Administration Technique to Minimize Epistaxis
The presence of epistaxis requires special attention to proper technique, as epistaxis is a known common side effect of all intranasal corticosteroids 3, 1, 4:
Proper Spray Technique:
- Shake the bottle well before each use 5
- Prime the pump (if new bottle or unused for >1 week): pump 10 times until fine mist appears 5
- Blow nose gently to clear nostrils 5
- Critical step for epistaxis prevention: Insert only the tip of the nozzle into the nostril and aim the spray AWAY from the nasal septum (toward the outer wall of the nose) 3, 5
- While sniffing gently, press down once or twice per nostril as directed 5
- Wipe nozzle with clean tissue after use 5
Why This Matters:
The nasal septum is the most common site of epistaxis, and directing the spray toward it increases bleeding risk. Patients should be explicitly instructed to angle the spray laterally (right hand for left nostril, left hand for right nostril helps achieve proper angle) 3.
Monitoring for Epistaxis
Periodic examination of the nasal septum is essential to check for mucosal erosions, which may indicate increased risk for septal perforation (though rare with intranasal corticosteroids) 3. If epistaxis becomes problematic:
- Verify proper spray technique (most common cause of bleeding)
- Examine nasal mucosa for erosions
- Consider temporary dose reduction or brief treatment interruption if severe
- Ensure adequate nasal humidification
Evidence on Epistaxis Risk
Meta-analysis data shows mometasone furoate is associated with moderate epistaxis risk among intranasal corticosteroids 4. However, this must be balanced against its superior efficacy for controlling all four major rhinitis symptoms (congestion, rhinorrhea, sneezing, itching) compared to other medication classes 3.
Epistaxis rates in clinical trials:
- Mometasone furoate: epistaxis reported as common adverse event 1, 6
- Generally mild and self-limiting 6
- Does not typically require treatment discontinuation 6, 7
Duration and Efficacy Considerations
- Onset of action: Clinically significant relief begins within 12 hours, with median time to moderate relief at 35.9 hours 8
- Optimal efficacy: Achieved with daily use; inconsistent use reduces effectiveness 5
- Long-term use: Safe for extended periods without HPA axis suppression at recommended doses 6, 2, 9
- Children: Should use lowest effective dose; check with physician if needed >2 months per year 5
Clinical Context
Intranasal corticosteroids like Nasonex are the most effective medication class for rhinitis and should be considered first-line therapy, even before antihistamines, particularly for moderate-to-severe symptoms 3. The presence of epistaxis is not a contraindication to use, but rather requires proper technique education and monitoring.
If symptoms don't improve after 1 week of proper use, reassess the diagnosis 5. Consider whether this is truly allergic/inflammatory rhinitis versus other causes (rhinitis medicamentosa from decongestant overuse, structural abnormalities, etc.).
Key Pitfalls to Avoid
- Improper spray direction: Most common cause of epistaxis and treatment failure
- Inadequate priming: Results in subtherapeutic dosing
- Irregular use: Reduces efficacy; daily use is essential
- Expecting immediate relief: Set realistic expectations about 12-36 hour onset
- Failing to examine nasal mucosa: Periodic inspection prevents serious complications
- Using topical decongestants concurrently for >3 days: Risk of rhinitis medicamentosa 3